| Comparison of self-reported cognitive difficulties in a national sample of long-term cancer survivors and cancer-naive controls. | |
| | |
MedLine Citation:
|
PMID: 22221723 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: Evidence that long-term cancer survivors (LTCS) experience greater cognitive dysfunction than individuals without cancer is mixed. This analysis of a population-based sample of United States residents compares self-reported cognitive difficulties in LTCS and cancer naïve controls (CNC), controlling for psychiatric disorders. METHODS: National Comorbidity Survey-Replication (NCS-R) interviews were conducted in a nationally-representative sample of 9282 people, of whom 5692 were assessed for cancer history. Long-term survivors of adult cancers were defined as individuals who were at least 18 years old at time of diagnosis; greater than 5 years following diagnosis; and with cancer reportedly in remission or cured. Cognitive dysfunction queries included two screening questions and five items drawn than the World Health Organization (WHO) Disability Assessment Schedule 2.0. Psychiatric disorders were identified using the WHO's Composite International Diagnostic Interview. Odds ratios and 95% confidence intervals were obtained from multivariable logistic regression models fit to evaluate the relationship between cancer status (LTCS versus CNC) and cognitive symptoms. RESULTS: Of NCS-R participants, 225 met criteria for LTCS and 3953 for CNC. Long-term cancer survivors and CNC screened positive for cognitive symptoms at a rate of 19.5% and 20.8%, respectively, for the first screen and 16.0% and 16.4%, respectively, for the second. Adjusting for demographic and psychiatric variables, LTCS did not carry increased odds of experiencing cognitive symptoms [(OR) 1.00 (95% CI, .59 to 1.68); (OR) .95 (95 %CI, .57 to 1.59)]. CONCLUSIONS: Self-reported cognitive symptoms are common among LTCS and CNC. LTCS do not report cognitive symptoms with greater frequency. |
| | |
Authors:
|
Ilana M Braun; Sowmya R Rao; William F Pirl |
Related Documents
:
|
21726203 - Plasma soluble hla-g is a potential biomarker for diagnosis of colorectal, gastric, eso... 21919453 - Changing the energy habitat of the cancer cell in order to impact therapeutic resistance. 14995903 - Signature of a silent killer: expression profiling in epithelial ovarian cancer. |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Psychosomatics Volume: 53 ISSN: 1545-7206 ISO Abbreviation: Psychosomatics Publication Date: 2012 Jan-Feb |
Date Detail:
|
Created Date: 2012-01-06 Completed Date: 2012-04-11 Revised Date: 2012-04-24 |
Medline Journal Info:
|
Nlm Unique ID: 0376506 Medline TA: Psychosomatics Country: England |
Other Details:
|
Languages: eng Pagination: 68-74 Citation Subset: IM |
Copyright Information:
|
Copyright © 2012 The Academy of Psychosomatic Medicine. Published by Elsevier Inc. All rights reserved. |
Affiliation:
|
Dana-Farber Cancer Institute, Boston, MA 02215-5450, USA. ibraun@partners.org |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Antineoplastic Agents / adverse effects Attitude to Health Cognition Disorders / epidemiology* Comorbidity Diagnostic Self Evaluation Epidemiologic Methods Female Humans Interview, Psychological Male Memory Disorders / epidemiology Mental Disorders / epidemiology* Middle Aged Neoplasms / drug therapy, epidemiology*, psychology Socioeconomic Factors Survivors / psychology*, statistics & numerical data United States / epidemiology |
| Chemical | |
Reg. No./Substance:
|
0/Antineoplastic Agents |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Parental-reported health anxiety symptoms in 5- to 7-year-old children: the Copenhagen Child Cohort ...
Next Document: Escitalopram for severe asthma and major depressive disorder: a randomized, double-blind, placebo-co...